TMDX TransMedics Group Inc
Price (delayed)
$151.21
Market cap
$5.04B
P/E Ratio
1,890.13
Dividend/share
N/A
EPS
$0.08
Enterprise value
$5.2B
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need
Highlights
The revenue has soared by 137% YoY and by 21% from the previous quarter
The net income has soared by 129% QoQ and by 117% YoY
The quick ratio has plunged by 58% YoY and by 5% from the previous quarter
The gross margin has contracted by 12% YoY and by 2.7% from the previous quarter
Key stats
What are the main financial stats of TMDX
Market
Valuations
Earnings
Shares outstanding
33.36M
Market cap
$5.04B
Enterprise value
$5.2B
Price to earnings (P/E)
1,890.13
Price to book (P/B)
26.23
Price to sales (P/S)
13.96
EV/EBIT
326.97
EV/EBITDA
164.67
EV/Sales
14.49
Revenue
$358.76M
EBIT
$15.9M
EBITDA
$31.56M
Free cash flow
-$193.76M
Per share
Balance sheet
Liquidity
EPS
$0.08
Free cash flow per share
-$5.85
Book value per share
$5.77
Revenue per share
$10.83
TBVPS
$22.49
Total assets
$758.58M
Total liabilities
$568.68M
Debt
$516.49M
Equity
$189.89M
Working capital
$454.94M
Debt to equity
2.72
Current ratio
9.37
Quick ratio
8.18
Net debt/EBITDA
4.86
Margins
Efficiency
Dividend
EBITDA margin
8.8%
Gross margin
60.7%
Net margin
0.8%
Operating margin
-0.2%
Return on assets
0.4%
Return on equity
2%
Return on invested capital
2%
Return on capital employed
2.3%
Return on sales
4.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TMDX stock price
How has the TransMedics Group stock price performed over time
Intraday
-0.14%
1 week
8.54%
1 month
-11.2%
1 year
153.96%
YTD
91.57%
QTD
0.39%
Financial performance
How have TransMedics Group's revenue and profit performed over time
Revenue
$358.76M
Gross profit
$217.81M
Operating income
-$803,000
Net income
$3M
Gross margin
60.7%
Net margin
0.8%
The revenue has soared by 137% YoY and by 21% from the previous quarter
The net income has soared by 129% QoQ and by 117% YoY
The company's net margin has surged by 124% QoQ and by 107% YoY
TMDX's gross profit has surged by 109% year-on-year and by 18% since the previous quarter
Growth
What is TransMedics Group's growth rate over time
Valuation
What is TransMedics Group stock price valuation
P/E
1,890.13
P/B
26.23
P/S
13.96
EV/EBIT
326.97
EV/EBITDA
164.67
EV/Sales
14.49
TransMedics Group's EPS has surged by 125% QoQ and by 114% YoY
The stock's P/B is 132% more than its 5-year quarterly average of 11.3 and 41% more than its last 4 quarters average of 18.6
TMDX's equity is up by 31% year-on-year and by 19% since the previous quarter
The revenue has soared by 137% YoY and by 21% from the previous quarter
The P/S is 33% higher than the last 4 quarters average of 10.5 but 26% lower than the 5-year quarterly average of 18.8
Efficiency
How efficient is TransMedics Group business performance
TransMedics Group's return on sales has surged by 154% YoY
The ROIC has soared by 138% YoY
TransMedics Group's return on equity has surged by 128% QoQ and by 120% YoY
The ROA has soared by 127% since the previous quarter and by 109% year-on-year
Dividends
What is TMDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TMDX.
Financial health
How did TransMedics Group financials performed over time
The total assets is 33% more than the total liabilities
The quick ratio has plunged by 58% YoY and by 5% from the previous quarter
The company's current ratio has shrunk by 55% YoY and by 3.6% QoQ
The company's debt is 172% higher than its equity
TMDX's equity is up by 31% year-on-year and by 19% since the previous quarter
TMDX's debt to equity is down by 23% year-on-year and by 16% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.